ABBVUSNASDAQ / NYSE · United States
ABBVIE INC.
295.03USD+0.20%close 2026-11-13
Daily candles · 12 months
ABBV · 1DPerformance
1W
+1.3%1M
+4.1%3M
+17.9%6M
+40.2%YTD
+29.1%1Y
+27.0%52W low 190.75high 302.93
-2.6% from the 52-week high.
Trend
- vs 20-day average
- Above by 1.9%
- vs 50-day average
- Above by 7.1%
- vs 200-day average
- Above by 22.5%
- ATR (14d)
- 2.52%
- 10-day range
- 7.4%
- Volume vs 20-day avg
- 0.62×
Position size
- Risk per share
- 11.14 USD
- Shares
- 8
- Position value
- 2,360.24 USD
- % of account
- 23.6%
- Risk amount
- 89.12 USD
- 1R target
- 306.17
- 2R target
- 317.31
- 3R target
- 328.45
Fundamentals and earnings
- Market cap
- 521.50B
- P/E (trailing)
- 50.6
- P/E (forward)
- 18.2
- EPS (TTM / next yr)
- 5.83 / 16.20
- Dividend yield
- 2.35%
- Earnings date
- Oct 30, 2026
Listing
- Ticker
- ABBV US
- Yahoo / TradingView
- ABBV · NYSE:ABBV
- Keyword
- EOSE
- Mapped to
- EOS ENERGY ENTERPRISES, INC.EOSE US
Headlines
- Can IBM's Latest Quantum System Boost Illinois' Innovation Future?Zacks · 5d ago
- What Happens To Pfizer Stock If Patent Losses Outpace New Drugs?Trefis · 5d ago
- AbbVie Unit Says GLP-1 Patients Report Improved Satisfaction With Facial Appearance in 2 StudiesMT Newswires · 5d ago
- What State Street Health Care SPDR (XLV) Sold: Eli Lilly Leads on Nov. 5GuruFocus.com · 5d ago
- Zacks Investment Ideas feature highlights: Moderna, AbbVie, Eli Lilly and MerckZacks · 5d ago
- Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 MedicationsPR Newswire · 6d ago
Prices and fundamentals from Yahoo Finance, delayed. Not financial advice.